Alethia Biotherapeutics, Inc.

Alethia is focusing on bone loss in acute disorders, invasive carcinomas and on cancer-associated epithelial-to-mesenchymal transition, three areas for which there are very few therapeutic options. Corporate highlights; Privately-held Montreal-based biotechnology company; Engaged in the discovery and development of therapeutic mAbs against highly-disease tissue specific novel clinically-relevant targets; Currently having three pre-clinical programs with two INDs expected within the next 2 – 8 months; Extensive portfolio of highly-specific, novel and clinically-relevant targets using the proprietary STAR technology; Exploiting a powerful a proprietary target discovery technology with the potential to expand pipeline; Established strategic partnerships to access mAb generation, humanization, antibody drug conjugates, and CHO production technologies; Seasoned management and multi-disciplinary discovery and early-stage development team; Unencumbered pipeline with the potential for selected strategic partnerships on therapeutic mAbs.